Matthew J. Kuhn1, Howard A. Rowley2, Michael V. Knopp3, Kenneth R. Maravilla4, Zoran Rumboldt5
1Radiology, University of Illinois at Peoria, Peoria, IL, United States; 2Radiology, University of Wisconsin, Madison, WI, United States; 3Radiology, Ohio State University, Columbus, OH, United States; 4Radiology and Surgery, University of Washington, Seattle, WA, United States; 5Radiology, Medical University of South Carolina, Charleston, SC, United States
382 patients were randomized to receive 2 MR exams within 2 days to 2 weeks with equal 0.1mmo/kg doses of either gadobenate dimeglumine (N=382) or a comparator gadolinium agent. Blinded experts assessed post-contrast images for both qualitative (eg, global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference) and quantitative (eg, contrast-to-noise ratio [CNR]; percent lesion enhancement) efficacy parameters. In all six studies, images produced following administration of Gd-BOPTA demonstrated greater contrast enhancement, provided more diagnostic information including additional lesion detection, and were significantly preferred by experienced, blinded neuroradiologists.